Results
1 -
4 of
4Treatment of Patients in Third Relapse and Beyond Including Double-Refractory Disease, Personalized Therapy for Multiple Myeloma Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma, Cancer Chemotherapy and Pharmacology New drugs on the horizon. Treatment of myeloma in 2020, a perspective, memo - Magazine of European Medical Oncology Novel agents in the treatment of multiple myeloma: a review about the future, Journal of Hematology & Oncology